Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Neuropathic pain in individuals with sickle cell disease.

Sharma D, Brandow AM.

Neurosci Lett. 2019 Aug 24;714:134445. doi: 10.1016/j.neulet.2019.134445. [Epub ahead of print] Review.

PMID:
31454562
2.

Sickle Cell Disease.

Bender MA.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
2003 Sep 15 [updated 2017 Aug 17].

3.

Sickle cell disease pain management in adolescents: a literature review.

Wilson BH, Nelson J.

Pain Manag Nurs. 2015 Apr;16(2):146-51. doi: 10.1016/j.pmn.2014.05.015. Epub 2014 Aug 28. Review.

PMID:
25175555
4.

Sickle cell disease in mice is associated with sensitization of sensory nerve fibers.

Kenyon N, Wang L, Spornick N, Khaibullina A, Almeida LE, Cheng Y, Wang J, Guptill V, Finkel JC, Quezado ZM.

Exp Biol Med (Maywood). 2015 Jan;240(1):87-98. doi: 10.1177/1535370214544275. Epub 2014 Jul 28.

5.

Interventions for chronic kidney disease in people with sickle cell disease.

Roy NB, Fortin PM, Bull KR, Doree C, Trivella M, Hopewell S, Estcourt LJ.

Cochrane Database Syst Rev. 2017 Jul 3;7:CD012380. doi: 10.1002/14651858.CD012380.pub2. Review.

6.

Neuropathic pain in patients with sickle cell disease.

Brandow AM, Farley RA, Panepinto JA.

Pediatr Blood Cancer. 2014 Mar;61(3):512-7. doi: 10.1002/pbc.24838. Epub 2013 Oct 26.

7.

Targeting novel mechanisms of pain in sickle cell disease.

Tran H, Gupta M, Gupta K.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):546-555. doi: 10.1182/asheducation-2017.1.546. Review.

8.

Vaso-occlusive crisis in sickle cell disease: current paradigm on pain management.

Uwaezuoke SN, Ayuk AC, Ndu IK, Eneh CI, Mbanefo NR, Ezenwosu OU.

J Pain Res. 2018 Dec 11;11:3141-3150. doi: 10.2147/JPR.S185582. eCollection 2018. Review.

9.

Cost-effectiveness of adenotonsillectomy in reducing obstructive sleep apnea, cerebrovascular ischemia, vaso-occlusive pain, and ACS episodes in pediatric sickle cell disease.

Tripathi A, Jerrell JM, Stallworth JR.

Ann Hematol. 2011 Feb;90(2):145-50. doi: 10.1007/s00277-010-1048-4. Epub 2010 Aug 17.

PMID:
20714723
10.

Interventions for treating neuropathic pain in people with sickle cell disease.

Asnani MR, Francis DK, Brandow AM, Hammond Gabbadon CE, Ali A.

Cochrane Database Syst Rev. 2019 Jul 5;7:CD012943. doi: 10.1002/14651858.CD012943.pub2.

PMID:
31273755
11.

Sickle-cell pain: advances in epidemiology and etiology.

Smith WR, Scherer M.

Hematology Am Soc Hematol Educ Program. 2010;2010:409-15. doi: 10.1182/asheducation-2010.1.409.

PMID:
21239827
12.

Hydroxyurea (hydroxycarbamide) for sickle cell disease.

Nevitt SJ, Jones AP, Howard J.

Cochrane Database Syst Rev. 2017 Apr 20;4:CD002202. doi: 10.1002/14651858.CD002202.pub2. Review.

13.

Acute Vaso-Occlusive Pain is Temporally Associated with the Onset of Menstruation in Women with Sickle Cell Disease.

Sharma D, Day ME, Stimpson SJ, Rodeghier M, Ghafuri D, Callaghan M, Zaidi AU, Hannan B, Kassim A, Zempsky W, Wellons M, James A, Bruehl S, DeBaun MR.

J Womens Health (Larchmt). 2019 Feb;28(2):162-169. doi: 10.1089/jwh.2018.7147. Epub 2019 Jan 16.

PMID:
30648915
14.

Leukotriene pathway in sickle cell disease: a potential target for directed therapy.

Knight-Perry J, DeBaun MR, Strunk RC, Field JJ.

Expert Rev Hematol. 2009 Feb;2(1):57-68. doi: 10.1586/17474086.2.1.57. Review.

PMID:
21082995
15.

Spinal and afferent PKC signaling mechanisms that mediate chronic pain in sickle cell disease.

He Y, Wang ZJ.

Neurosci Lett. 2019 Jul 27;706:56-60. doi: 10.1016/j.neulet.2019.04.055. Epub 2019 Apr 30. Review.

PMID:
31051220
16.

Targeting novel mechanisms of pain in sickle cell disease.

Tran H, Gupta M, Gupta K.

Blood. 2017 Nov 30;130(22):2377-2385. doi: 10.1182/blood-2017-05-782003. Review.

17.

Interventions for preventing silent cerebral infarcts in people with sickle cell disease.

Estcourt LJ, Fortin PM, Hopewell S, Trivella M, Doree C, Abboud MR.

Cochrane Database Syst Rev. 2017 May 13;5:CD012389. doi: 10.1002/14651858.CD012389.pub2. Review.

18.

Safety and Utility of Quantitative Sensory Testing among Adults with Sickle Cell Disease: Indicators of Neuropathic Pain?

Ezenwa MO, Molokie RE, Wang ZJ, Yao Y, Suarez ML, Pullum C, Schlaeger JM, Fillingim RB, Wilkie DJ.

Pain Pract. 2016 Mar;16(3):282-93. doi: 10.1111/papr.12279. Epub 2015 Jan 12.

19.

Frequency of Hospitalizations for Pain and Association With Altered Brain Network Connectivity in Sickle Cell Disease.

Darbari DS, Hampson JP, Ichesco E, Kadom N, Vezina G, Evangelou I, Clauw DJ, Taylor Vi JG, Harris RE.

J Pain. 2015 Nov;16(11):1077-86. doi: 10.1016/j.jpain.2015.07.005. Epub 2015 Aug 18.

20.

Gabapentin alleviates chronic spontaneous pain and acute hypoxia-related pain in a mouse model of sickle cell disease.

Sadler KE, Langer SN, Menzel AD, Moehring F, Erb AN, Brandow AM, Stucky CL.

Br J Haematol. 2019 Oct;187(2):246-260. doi: 10.1111/bjh.16067. Epub 2019 Jun 27.

PMID:
31247672

Supplemental Content

Support Center